Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Romidepsin targets multiple survival signaling pathways in malignant T cells
Benigno C. Valdez, Jonathan E. Brammer, Yan Li, et al.
Blood Cancer Journal (2015) Vol. 5, Iss. 10, pp. e357-e357
Open Access | Times Cited: 65

Showing 1-25 of 65 citing articles:

HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma
Hong Zheng, Weipeng Zhao, Cihui Yan, et al.
Clinical Cancer Research (2016) Vol. 22, Iss. 16, pp. 4119-4132
Open Access | Times Cited: 299
HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases
Elizabeth Hull, McKale R. Montgomery, Kathryn J. Leyva
BioMed Research International (2016) Vol. 2016, pp. 1-15
Open Access | Times Cited: 270
Cyclic peptide drugs approved in the last two decades (2001–2021)
Huiya Zhang, Shiyu Chen
RSC Chemical Biology (2021) Vol. 3, Iss. 1, pp. 18-31
Open Access | Times Cited: 219
Cyclic Peptides as Drugs for Intracellular Targets: The Next Frontier in Peptide Therapeutic Development
Laura K. Buckton, Marwa N. Rahimi, Shelli R. McAlpine
Chemistry - A European Journal (2020) Vol. 27, Iss. 5, pp. 1487-1513
Closed Access | Times Cited: 131
An overview of cutaneous T cell lymphomas
Nooshin Bagherani, Bruce R. Smoller
F1000Research (2016) Vol. 5, pp. 1882-1882
Open Access | Times Cited: 97
Targeting histone deacetylases in T-cell lymphoma
Alison J. Moskowitz, Steven M. Horwitz
Leukemia & lymphoma/Leukemia and lymphoma (2016) Vol. 58, Iss. 6, pp. 1306-1319
Open Access | Times Cited: 91
Multi_CycGT: A Deep Learning-Based Multimodal Model for Predicting the Membrane Permeability of Cyclic Peptides
Lujing Cao, Zhenyu Xu, Tianfeng Shang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 3, pp. 1888-1899
Closed Access | Times Cited: 14
Converting “cold” to “hot”: epigenetics strategies to improve immune therapy effect by regulating tumor‐associated immune suppressive cells
Yijia Tang, Guangzu Cui, Haicong Liu, et al.
Cancer Communications (2024) Vol. 44, Iss. 6, pp. 601-636
Open Access | Times Cited: 12
Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma
Ping Zhang, Mingzhi Zhang
Clinical Epigenetics (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 68
Role of Natural Products in Modulating Histone Deacetylases in Cancer
Myriam Mérarchi, Gautam Sethi, Muthu K. Shanmugam, et al.
Molecules (2019) Vol. 24, Iss. 6, pp. 1047-1047
Open Access | Times Cited: 52
Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy
Eftiola Pojani, Daniela Barlocco
Current Medicinal Chemistry (2020) Vol. 28, Iss. 7, pp. 1290-1303
Closed Access | Times Cited: 44
Emerging Role of Epigenetic Modifiers in Breast Cancer Pathogenesis and Therapeutic Response
Richard S. Lee, Kirti Sad, Dorelle V. Fawwal, et al.
Cancers (2023) Vol. 15, Iss. 15, pp. 4005-4005
Open Access | Times Cited: 14
Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients
Benoit M. Cyrenne, Julia M. Lewis, Jason Weed, et al.
Blood (2017) Vol. 130, Iss. 19, pp. 2073-2083
Open Access | Times Cited: 48
Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease
Alessandro Broccoli, Lisa Argnani, Pier Luigi Zinzani
Cancer Treatment Reviews (2017) Vol. 60, pp. 120-129
Closed Access | Times Cited: 43
Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells
Benigno C. Valdez, Yang Li, David Murray, et al.
Oncotarget (2017) Vol. 9, Iss. 3, pp. 3908-3921
Open Access | Times Cited: 41
Current treatment strategies targeting histone deacetylase inhibitors in acute lymphocytic leukemia: a systematic review
Yingjun Zhang, Ge Zhang, Yuefang Wang, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 4
Histone deacetylase inhibitors for leukemia treatment: current status and future directions
Mohammad‐Salar Hosseini, Zohreh Sanaat, Mohammad Amin Akbarzadeh, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 4
Enhancement of the in vitro anti-leukemic effect of the histone deacetylase inhibitor Romidepsin using Poly-(D,L-lactide-co-glycolide) nanoparticles as a drug carrier
Pinyadapat Aroonthongsawat, Siriphan Manocheewa, Chatchawan Srisawat, et al.
European Journal of Pharmaceutical Sciences (2025), pp. 107043-107043
Open Access
MultiCycPermea: accurate and interpretable prediction of cyclic peptide permeability using a multimodal image-sequence model
Zixu Wang, Yangyang Chen, Yifan Shang, et al.
BMC Biology (2025) Vol. 23, Iss. 1
Open Access
Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study
Dai Maruyama, Kensei Tobinai, Michinori Ogura, et al.
International Journal of Hematology (2017) Vol. 106, Iss. 5, pp. 655-665
Closed Access | Times Cited: 35
Loss of genomic integrity induced by lysosphingolipid imbalance drives ageing in the heart
Gaurav Ahuja, Deniz Bartsch, Wenjie Yao, et al.
EMBO Reports (2019) Vol. 20, Iss. 4
Open Access | Times Cited: 32
Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics
Daniel J. García-Domínguez, Lourdes Hontecillas‐Prieto, Natalia Palazón‐Carrión, et al.
Cancers (2022) Vol. 14, Iss. 6, pp. 1469-1469
Open Access | Times Cited: 16
Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma
Sanne Venneker, Alwine B. Kruisselbrink, Zuzanna Baranski, et al.
Cancers (2020) Vol. 12, Iss. 12, pp. 3589-3589
Open Access | Times Cited: 26
Enhanced antitumoral activity of TLR7 agonists via activation of human endogenous retroviruses by HDAC inhibitors
David Díaz-Carballo, Sahitya Saka, Ali H. Acikelli, et al.
Communications Biology (2021) Vol. 4, Iss. 1
Open Access | Times Cited: 22
Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies
Elisabetta Fratta, Barbara Montico, Aurora Rizzo, et al.
Oncotarget (2016) Vol. 7, Iss. 35, pp. 57327-57350
Open Access | Times Cited: 25
Page 1 - Next Page

Scroll to top